American Association for Cancer Research
00085472can210052-sup-257683_3_supp_7223380_qvlx2n.pdf (1.62 MB)

Supplemental Figure 2 from PPARα Agonist Fenofibrate Enhances Cancer Vaccine Efficacy

Download (1.62 MB)
journal contribution
posted on 2023-03-31, 04:28 authored by Arezki Chekaoui, Hildegund C.J. Ertl

The cartoon describes the experimental set-up used to generate the results shown in Figure 2. Groups of mice were vaccinated with AdC68-gDMelapoly. 3, 5 or 7 days later fenofibrate or diluent treatment was started and continued daily till day 17. One day after the last group finished treatment mice were euthanized and their splenic CD44+CD8+ cells were analyzed.


Department of Defense



Reducing metabolic stress within the tumor microenvironment (TME) could be essential for improving the efficacy of cancer immunotherapy. Using a mouse model of melanoma, we show here that appropriately timed treatment with the PPARα agonist fenofibrate improves the ability of a T cell–inducing cancer vaccine to delay tumor progression. Fenofibrate reduced the use of glucose by tumor and stromal cells in the TME and promoted the use of fatty acids for their metabolic needs. The glucose within the TME was in turn available for use by vaccine-induced tumor-infiltrating CD8+ T cells, which improved their ability to slow tumor progression. Early fenofibrate treatment 3 days after vaccination improved functions of circulating CD8+ T cells but failed to significantly affect tumor-infiltrating lymphocyte (TIL) metabolism or decrease tumor progression. In contrast, delaying treatment until day 5 after vaccination modified TIL metabolism and augmented the vaccine's ability to slow tumor progression. In summary, our findings reveal that a PPARα agonist can increase the efficacy of a cancer vaccine by reprogramming cells within tumors to increase fatty acid metabolism, providing T cells access to glucose in the TME. These findings suggest that metabolic manipulations using already approved drugs may offer an easy pathway to increase the efficacy of vaccines against solid tumors.

Usage metrics

    Cancer Research



    Ref. manager